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ABSTRACT
Purpose. The role of carbohydrate antigen (CA) 19-9 in
the evaluation of patients with resectable pancreatic cancer
treated with neoadjuvant therapy prior to planned surgical
resection is unknown. We evaluated CA 19-9 as a marker
of therapeutic response, completion of therapy, and sur-
vival in patients enrolled on two recently reported clinical
trials.
Patients and Methods. We analyzed patients with radio-
graphically resectable adenocarcinoma of the head/
uncinate process treated on two phase II trials of neoad-
juvant chemoradiation. Patients without evidence of
disease progression following chemoradiation underwent
pancreaticoduodenectomy (PD). CA 19-9 was evaluated in
patients with a normal bilirubin level.
Results. We enrolled 174 patients, and 119 (68%) com-
pleted all therapy including PD. Pretreatment CA 19-9
\37 U/ml had a positive predictive value (PPV) for com-
pleting PD of 86% but a negative predictive value (NPV)
of 33%. Among patients without evidence of disease at
last follow-up, the highest pretreatment CA 19-9 was
1,125 U/ml. Restaging CA 19-9 \61 U/ml had a PPV of
93% and a NPV of 28% for completing PD among resect-
able patients. The area under the receiver-operating
characteristics curve of pretreatment and restaging CA 19-9
levels for completing PD was 0.59 and 0.74, respectively.
We identiﬁed no association between change in CA 19-9
and histopathologic response (P = 0.74).
Conclusions. Although the PPV of CA 19-9 for com-
pleting neoadjuvant therapy and undergoing PD was high,
its clinical utility was compromised by a low NPV. Deci-
sion-making for patients with resectable PC should remain
based on clinical assessment and radiographic staging.
Enthusiasm for the use of neoadjuvant therapy for
patients with potentially resectable pancreatic adenocarci-
noma (PC) has grown as clinicians have increasingly
recognized ‘‘resectable’’ PC as a systemic disease. Neo-
adjuvant treatment sequencing allows for early treatment of
the extrapancreatic micrometastases present in the majority
of patients with localized PC and improves the selection of
patients for surgery by limiting resection to those with
stable or responding disease—an important consideration
for an operation with a deﬁned mortality and signiﬁcant
morbidity.
1 Although no randomized trial has demon-
strated the superiority of preoperative over postoperative
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multi-institutional trials, and population-based analyses
encourage further study of novel treatment sequencing in
patients with stage I and II PC.
2–6
In addition to neoadjuvant treatment sequencing, another
tool to more accurately select patients for surgery might be
a serum tumor marker. Carbohydrate antigen 19-9 (CA 19-
9) has long been accepted as a measure of PC tumor burden,
and as such it has been utilized as a prognostic marker for
patients with all stages of disease.
7 Among patients with
resectable PC, preoperative levels correlate with tumor
resectability and postoperative survival, and postoperative
levels predict survival duration in patients treated with
adjuvant therapies.
8–12 For patients with advanced PC,
pretreatment CA 19-9 has been reported to be prognostic
and the change in serum levels over the course of treatment
has been used as an index of treatment response.
13,14
Serum CA 19-9 is a useful tumor marker in certain
clinical scenarios, but its added prognostic value beyond
radiographic and clinical staging for patients with resect-
able PC is unclear. Moreover, although a few studies have
examined CA 19-9 levels of patients who had been treated
with chemotherapy or chemoradiation prior to surgery, only
one small study has evaluated serial CA 19-9 levels of
patients with resectable PC treated with a multidisciplinary
program of neoadjuvant therapy and planned resection.
15–18
To clearly deﬁne the role of CA 19-9 in this context, we
analyzed patients with potentially resectable PC of the
pancreatic head or uncinate process treated on two recently
reported phase II trials of neoadjuvant chemoradiation.
2,3
PATIENTS AND METHODS
Between 1998 and 2006, 176 patients were enrolled on
two neoadjuvant trials. In the ﬁrst trial (Gem-XRT),
induction therapy consisted of seven, weekly intravenous
infusions of gemcitabine (400 mg/m
2) and concomitant
radiation therapy (30 Gy in ten fractions).
2 Patients on the
second trial (Gem-Cis-XRT) received four doses of gem-
citabine (750 mg/m
2) and cisplatin (30 mg/m
2) followed by
gemcitabine-based chemoradiation.
3 Of the 176 patients,
we excluded 2 from analysis: 1 with an adenocarcinoma of
the ampulla of Vater, and 1 with an adenocarcinoma arising
within an intraductal papillary mucinous neoplasm.
Eligibility requirements of both studies were identical.
2,3
Brieﬂy,allpatientshadaradiographicallyvisiblemassinthe
pancreatic head or uncinate process and pathologically
conﬁrmed adenocarcinoma which was staged as potentially
resectable on the basis of objective computed tomography
(CT) criteria: (1) no evidence of extrapancreatic disease, (2)
absence of tumor extension to the superior mesenteric artery
(SMA)orceliacaxis,and(3)noevidenceofocclusionofthe
superior mesenteric vein (SMV) or SMV–portal vein (PV)
conﬂuence.
19 When necessary, biliary decompression was
accomplished endoscopically. All patients underwent com-
plete restaging evaluation 4–6 weeks following completion
of chemoradiation. In the absence of disease progression,
patients underwent laparotomy for pancreaticoduodenecto-
my (PD); the decision to operate was not inﬂuenced by CA
19-9. Histopathologic response to preoperative therapy was
scored by a gastrointestinal pathologist.
20 Follow-up was
performed on a standard schedule.
Neither trial protocol mandated measurement of serum
CA 19-9 but levels were typically measured both prior to
(pretreatment level) and following (restaging level) induc-
tion therapy. Serum acquired prior to October 6, 2004 was
assayed for CA 19-9 by Quest Diagnostics (Madison, NJ).
Subsequent samples were assayed using a similar method at
The University of Texas M. D. Anderson Cancer Center.
Serum CA 19-9 levels obtained in association with total
bilirubin B1.5 mg/dl were considered evaluable. Levels
associated with total bilirubin [1.5 mg/dl were excluded
from analysis, as biliary obstruction may lead to an increase
in serum levels of CA 19-9.
7,21 CA 19-9 may also not be an
accurate reﬂection of disease status in patients who express
the Lewis
a-b- genotype.
22 However, genotyping was not
performed prospectively and could not be performed ret-
rospectively, so ‘‘nonproducers’’ could not be distinguished
from patients who produce CA 19-9 but presented with
values below the assay sensitivity threshold (\8 U/ml and
\1 U/ml prior to and after October 6, 2004, respectively).
For the purpose of this analysis, below-threshold serum CA
19-9 values were recorded as the threshold value.
Pearson chi-square and Student’s t test were used to
compare variables. Overall survival was calculated from
date of tissue diagnosis and was estimated by the Kaplan–
Meier method. The log-rank test was used to compare
survival curves. Receiver-operating characteristics (ROC)
curves were constructed by using SAS/STAT 9.1.3 (SAS
Institute Inc., Cary, NC) to evaluate the ability of CA 19-9
to predict completion of all therapy including PD. The area
under the curve (AUC) was calculated to compare the
relative value of each test. Optimal cutoff values for each
test were established by identifying the cutoff at which the
sensitivity and speciﬁcity of the test were simultaneously
maximized. SPSS 17.0 (SPSS Inc., Chicago, IL) was used
for all other statistical analyses. Values of P B 0.05 were
considered to be signiﬁcant for all comparisons.
RESULTS
Median survival of the 174 patients was 20 months [95%
conﬁdence interval (CI) 17.0–22.7 months]. Following
chemoradiation, 139 (80%) of the 174 patients remained
CA 19-9 in Neoadjuvant Chemoradiation 1795candidatesfor PDbased on the clinical restaging evaluation.
Of these, 119 (86%) underwent resection and had a median
survival of 32 months (95% CI 25.4–37.6 months). Median
survival of all patients (P = 0.08) and resected patients
(P = 0.21) did not differ between treatment protocols.
Median follow-up of surviving patients was 78 months.
Pretreatment CA 19-9 was assayed in 166 (95%) of 174
patients and was evaluable in 99 (median 145 U/ml, mean
595 ± 1,233 U/ml, range 2–8,614 U/ml); the 67 remaining
patients had hyperbilirubinemia which precluded accurate
evaluation of CA 19-9 levels. Restaging CA 19-9 was
assayed in 133 (76%) of 174 patients and was evaluable in
129 (median 44 U/ml, mean 279 ± 912 U/ml, range 1–
6,926 U/ml); the 4 remaining patients had a total bilirubin
[1.5 mg/dl and were excluded from analysis. Of the 99
patients with an evaluable pretreatment CA 19-9 level, 82
(83%) had an evaluable restaging CA 19-9 (median 42 U/
ml, mean 316 ± 1,078 U/ml, range 1–6,926 U/ml). The
demographics, clinical factors, and outcomes of patients
with and without evaluable CA 19-9 levels at each time
point were similar (Table 1).
Association of Pretreatment CA 19-9 with PD,
Postoperative Recurrence, and Survival
Of 99 patients with an evaluable pretreatment serum CA
19-9 level, 70 (71%) completed all therapy including PD
(median 129 U/ml, mean 581 ± 1,364 U/ml, range 2–
8,614 U/ml) and 29 patients did not (median 173 U/ml,
mean 629 ± 856 U/ml, range 12–3,365 U/ml, P = 0.9).
The area under the ROC curve for pretreatment CA 19-9 as
a marker of completing all therapy including surgical
resection was 0.59 (95% CI 0.47–0.71); the optimal cutoff
which simultaneously maximized both the sensitivity (54%)
and speciﬁcity (55%) of the test was 149 U/ml (Fig. 1).
Pretreatment CA 19-9 was associated with a low nega-
tive predictive value (NPV) for completing all therapy
including PD at all cutoff values (Table 2). Among 15
patients without documented recurrence following PD, the
highest pretreatment CA 19-9 level was 1,125 U/ml
(Fig. 2). In contrast, the positive predictive value (PPV) of
pretreatment CA 19-9 for undergoing PD was considerably
higher. Patients with a pretreatment CA 19-9 level within
the normal range had more favorable survival than those
with an elevated pretreatment CA 19-9 (P = 0.02),
although signiﬁcance was not maintained when evaluating
only those patients who underwent PD (P = 0.08).
Association of Restaging CA 19-9 with PD,
Postoperative Recurrence, and Survival
Of the 129 patients in whom restaging levels were
evaluable,108(84%)hadnoevidenceofdiseaseprogression
and performance status sufﬁcient for surgery following
induction therapy (median restaging CA 19-9 40 U/ml,
mean 109 ± 290 U/ml, range 1–2,699 U/ml) and21 didnot
(median restaging CA 19-9 372 U/ml, mean 1,152 ±
1,981 U/ml, range 13–6,927 U/ml, P\0.001). In all, 93
(72%) of 129 patients completed all therapy including PD
(median restaging CA 19-9 34 U/ml, mean 83 ± 150 U/ml,
range 1–934 U/ml) and 36 patients did not (median
106 U/ml, mean 785 ± 1,619 U/ml, range 7–6,927 U/ml,
P\0.001).
The AUC for restaging CA 19-9 as a marker of com-
pleting all therapy including PD was 0.74 (95% CI 0.64–
0.84); the cutoff that maximized both sensitivity (72%) and
speciﬁcity (69%) of this test was 61 U/ml (Table 3, Fig. 1).
Independently, the optimal cutoff of 61 U/ml was associ-
ated with an NPV of 49%. The NPV of this cutoff was even
lower (28%) when the test was applied only to patients who
were considered resectableuponrestaging; thetesttherefore
had little power to identify patients with radiographically
occult disease progression. The highest restaging CA 19-9
level in patients who underwent potentially curative PD was
934 U/ml (Fig. 3). In contrast, the PPV of the test for
completing all therapy including PD was 86% at a cutoff of
61 U/ml; when evaluated only in the 108 patients with
evaluable restaging levels and a performance status suitable
for surgery and no evidence of disease progression, the PPV
was 93%.
Although restaging CA 19-9 at all cutoff levels was a
useful prognostic indicator with regard to overall survival,
signiﬁcance was not maintained when only patients who
underwent PD were considered.
Change in CA 19-9 and Correlation with PD, Survival,
and Treatment Effect
Of 82 patients in whom both pretreatment and restaging
CA 19-9 levels were evaluable, pretreatment CA 19-9 was
\37 U/ml in 18 (22%) patients. CA 19-9 remained within
the normal range upon restaging in 16 (89%) of these 18
patients; in the remaining 2 patients, CA 19-9 increased
only marginally (to 44 and 74 U/ml). Therefore, we ana-
lyzed the signiﬁcance of change in serum CA 19-9 between
pretreatment and restaging by examining only the 64
patients with pretreatment CA 19-9 above the upper limit
of normal. Overall, the 52 patients in whom CA 19-9 levels
decreased had more favorable survival than the 12 patients
in whom levels remained stable or increased [25.7 months
(95% CI 18.5–32.9 months) versus 10.4 months (95% CI
0–21.4 months), P = 0.01], and were more likely to
undergo PD (77% versus 42%, P = 0.02). However, the
median survival of the ﬁve patients in whom CA 19-9 did
not change or increased over the course of treatment but
who underwent PD was similar to that of the 40 patients
1796 M. H. G. Katz et al.who underwent PD after a decline in CA 19-9 [20.9 months
(95% CI 10.7–31.1 months) versus 28.3 months (95% CI
23.8–32.9 months), P = 0.41]. The PPV and NPV of a drop
in CA 19-9 to predict PD was 77% and 58%, respectively;
when evaluated at restaging only in 54 patients taken
to surgery, the PPV and NPV were 89% and 44%,
respectively.
In the 59 patients with both evaluable pretreatment and
restaging CA 19-9 levels and a treatment effect score from
the PD specimen, no association was observed between the
change in serum CA 19-9 over the course of induction
therapy and the grade of treatment effect observed in the
surgical specimen (P = 0.74). Similarly, no association
was observed when we analyzed only the 44 patients who
underwent PD and in whom pretreatment CA 19-9 was
above the upper limit of normal (P = 0.43).
DISCUSSION
Patients with resectable PC who undergo PD beneﬁt
from adjuvant therapy; current trials for resectable disease
no longer have a control arm which receives surgery
alone.
12,23,24 Unfortunately, up to 56% of patients do not
receive postoperative therapy when planned, due largely to
delayed surgical recovery or early tumor recurrence.
25–27
Neoadjuvant treatment sequencing ensures that all patients
with resectable PC who undergo PD receive multimodality
treatment. Neoadjuvant strategies also lead to lower than
TABLE 1 Demographic proﬁle, clinical factors, and outcomes of 174 patients with resectable PC treated with neoadjuvant chemoradiation
Clinical factor Total
(%)
Pretreatment
CA 19-9
evaluable
Pretreatment
CA 19-9 not
evaluable
P Restaging
CA 19-9
evaluable
Restaging
CA 19-9 not
evaluable
P Pretreatment
and restaging
CA 19-9 both
evaluable
Pretreatment
and restaging
CA 19-9 both
not evaluable
P
No. of Patients 174 99 75 129 45 82 92
Demographics
Gender, no. (%) 0.19 0.27 0.12
Male 104 (60) 55 (56) 49 (65) 74 (57) 30 (67) 44 (54) 60 (65)
Female 70 (40) 44 (44) 26 (35) 55 (43) 15 (33) 38 (46) 32 (35)
Age, years. 0.04 0.78 0.02
Median (mean) 64 (63) 62 (61) 66 (64) 64 (63) 64 (62) 62 (61) 66 (64)
Range 38–80 38–80 43–79 38–80 43–77 38–80 43–79
Treatment factors
Treatment protocol, no. (%) 0.23 0.001 0.05
Gem-XRT 86 (49) 45 (46) 41 (55) 54 (42) 32 (71) 34 (42) 52 (57)
Gem-Cis-XRT 88 (51) 54 (54) 34 (45) 75 (58) 13 (29) 48 (58) 40 (43)
Resected, no. (%) 0.45 0.08 0.20
Yes 119 (68) 70 (71) 49 (65) 93 (72) 26 (58) 60 (73) 59 (64)
No 55 (32) 29 (29) 26 (35) 36 (28) 19 (42) 22 (27) 33 (36)
Recurred, no. (%)
a 0.51 0.59 0.65
Yes 77 (65) 47 (67) 30 (61) 59 (63) 18 (69) 40 (67) 37 (63)
No 42 (35) 23 (33) 19 (39) 34 (37) 8 (31) 20 (33) 22 (37)
Time to recurrence, months
Resected patients 21.0 24.3 17.2 0.93 24.3 15.8 0.40 24.3 17.2 0.96
95% CI 12.9–29.0 14.5–34.1 4.4–30.0 14.5–34.0 8.2–23.4 15.2–33.3 3.0–31.4
Median OS, months
All patients 19.8 22.9 16.9 0.30 21.7 15.3 0.03 23.9 17.4 0.20
95% CI 17.0–22.7 17.2–28.6 12.6–21.2 16.5–26.9 12.1–18.6 17.7–30.0 13.3–21.5
Resected patients 31.5 33.6 31.5 0.65 34.0 22.7 0.22 33.6 31.5 0.69
95% CI 25.4–37.6 26.8–40.4 13.7–49.2 26.9–41.0 17.1–28.3 26.6–40.7 17.6–45.4
Unresected patients 10.3 10.3 10.2 0.23 10.2 10.3 0.76 9.6 10.3 0.27
95% CI 8.8–11.9 6.8–13.9 8.3–12.0 8.4–12.0 5.9–14.8 6.8–12.4 8.6–12.0
CI conﬁdence interval, Gem-XRT gemcitabine-based chemoradiation, Gem-Cis-XRT systemic gemcitabine/cisplatin followed by gemcitabine-
based chemoradiation
a One patient had a new primary which was counted as recurrence
CA 19-9 in Neoadjuvant Chemoradiation 1797expected rates of lymphatic metastasis and positive surgi-
cal margins, enrich the population of patients who undergo
PD with those most likely to beneﬁt from surgery, and
contribute to actual 5-year survival rates as high as
27%.
28–30 Successful neoadjuvant treatment approaches
require sequential staging evaluations to select those
patients who will beneﬁt from surgery—perhaps best
considered as one of the earliest forms of personalized
cancer care. We performed this analysis to determine
whether CA 19-9 could prospectively identify those
patients in whom radiographically occult advanced disease
will preclude completion of a multidisciplinary strategy
employing neoadjuvant therapy and PD.
An elevated CA 19-9 level at diagnosis in patients with
radiographically resectable PC has been reported to signify
occult disease that will prohibit primary resection.
8,10 Our
results suggest that this is not necessarily the case when
surgery is preceded by induction therapy. Indeed, of 78
patients with an evaluable pretreatment CA 19-9 level
above the normal range, 52 (67%) underwent PD, of whom
15 (22%) died of another cause or had not recurred at last
follow-up. All patients in our study with an evaluable
pretreatment CA 19-9 level greater than 1,125 U/ml either
did not undergo PD or ultimately recurred after PD.
However, although small patient numbers preclude rigor-
ous statistical analysis, it is interesting that 9 of 16 (56%)
patients with radiographically resectable disease and a
pretreatment CA 19-9 level C 1,000 U/ml underwent PD
following neoadjuvant therapy, only 4 of these 9 patients
recurred within 2 years, and the median overall survival of
these resected patients approached 3 years. It may be that
the antitumor effects of induction therapy alter the expec-
ted relationship between CA 19-9 and tumor burden over
time. Our study assessed CA 19-9 only in the setting of
normal bilirubin and included a more homogenous popu-
lation of patients than prior studies, which also may have
made differences between patient subgroups more subtle.
Either way, these data support caution in the use of pre-
treatment CA 19-9 as an eligibility criterion for enrollment
into clinical trials of neoadjuvant therapies for patients with
resectable PC, as has been employed in trials of postop-
erative therapy (i.e., CONKO-001).
12
Pretreatment CA 19-9 has also been reported to be a
marker of overall prognosis for patients treated with initial
surgery.
8,31 In this analysis, pretreatment CA 19-9 within
the normal range was associated with favorable overall
survival. Our inability to demonstrate similar prognostic
power when a cutoff of 37 U/ml was applied to the sub-
group of patients who underwent PD may be due to the
relatively small number of patients analyzed. Nonetheless,
1.0
0.8
0.6
0.4
0.2
0 1.0 
1 - Specificity 
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FIG. 1 Receiver-operating characteristics (ROC) curves for pretreat-
ment and restaging serum CA 19-9 levels as predictors of completing
all therapy including pancreaticoduodenectomy. The area under the
curve (AUC) and optimal cutoff values for pretreatment and restaging
CA 19-9 were 0.59 (95% CI 0.47–0.71), 149 U/ml and 0.74 (95% CI
0.64–0.84), 61 U/ml, respectively
TABLE 2 Resection rate and overall survival of 99 patients with evaluable pretreatment CA 19-9 levels stratiﬁed by cutoff
Pretreatment CA
19-9 (U/ml)
Total patients Resected patients
N (%) Overall survival,
months (95% CI)
P Resected n (%) P Test characteristics for
undergoing resection
Overall survival,
months (95% CI)
P
Evaluable 99 22.9 (17.2–28.6) 70 (71) 33.6 (26.8–40.4)
\37 21 (21) 52.8 (5.4–100.1) 0.02 18 (86) 0.09 Sens 26% Spec 90% 83.4 (21.9–145.0) 0.08
C37 78 (79) 21.2 (16.7–25.7) 52 (67) PPV 86% NPV 33% 28.1 (22.8–33.4)
\149
a 51 (52) 25.7 (18.0–33.4) 0.08 38 (75) 0.39 Sens 54% Spec 55% 12.8 (13.4–63.7) 0.20
C149
a 48 (48) 20.9 (12.3–29.5) 32 (67) PPV 75% NPV 33% 28.3 (18.3–38.4)
\200 58 (59) 22.9 (16.0–29.7) 0.37 41 (71) 0.99 Sens 59% Spec 41% 35.2 (20.5–50.0) 0.40
C200 41 (41) 21.4 (14.6–28.2) 29 (71) PPV 71% NPV 29% 31.0 (20.2–41.8)
\1,000 83 (84) 22.9 (17.4–28.3) 0.34 61 (73) 0.17 Sens 87% Spec 24% 33.6 (26.5–40.7) 0.98
C1,000 16 (16) 19.7 (0–41.7) 9 (56) PPV 73% NPV 44% 35.9 (12.2–59.6)
Sens sensitivity, Spec speciﬁcity, PPV positive predictive value, NPV negative predictive value
a Optimal pretreatment CA 19-9 cutoff determined by receiver-operating characteristics (ROC) analysis
1798 M. H. G. Katz et al.our data, combined with those of Berger et al., suggest that
a normal CA 19-9 level upon diagnosis may indicate
slightly more favorable tumor biology independent of the
initial therapeutic approach.
31
Response of CA 19-9 to surgical and adjuvant therapy
has been reported to be a measure of therapeutic efﬁ-
cacy.
8,11 Four analyses have examined the change in CA
19-9 over the course of nonoperative therapies prior to
surgery. Three of these were small studies analyzing pri-
marily patients with advanced, nonsurgical disease, who
were treated in the absence of a deﬁned plan for resec-
tion.
16–18 The results of these studies suggested the
possibility that CA 19-9 might be used as a crude measure
of response to preoperative therapy. However, the
heterogeneity of the patient populations studied makes this
conclusion difﬁcult to apply to individual patients with
resectable disease who are being considered for neoadju-
vant treatment prior to planned PD. Indeed, a recent
prospective study of neoadjuvant chemoradiation prior to
planned resection in 28 patients with resectable PC was
unable to demonstrate any correlation between change in
CA 19-9 and therapeutic response or ultimate resectabil-
ity.
15 Importantly, this study was small and did not take
into account the effects of hyperbilirubinemia; the changes
observed in CA 19-9 over the course of induction therapy
may have been inﬂuenced by biliary decompression and
not the anticancer therapy alone.
Data from the 82 patients in our study in whom both
pretreatment and restaging CA 19-9 levels were evaluable
10,000
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FIG. 2 Pretreatment serum CA 19-9 levels of patients stratiﬁed by
resection and recurrence status at last follow-up. Of 78 patients with
pretreatment CA 19-9 above normal, 52 (67%) underwent resection,
of whom 15 (22%) died of another cause or had not recurred at last
follow-up. Y-axis scale is Log10. Horizontal line represents 37 U/ml
TABLE 3 Resection rate and overall survival of 129 patients with evaluable restaging CA 19-9 levels stratiﬁed by cutoff
Restaging CA
19-9 (U/ml)
Total patients Resected patients
N (%) Overall survival,
months (95% CI)
P Resected
n (%)
P Test characteristics for
undergoing resection
Overall survival,
months (95% CI)
P
Evaluable 129 21.7 (16.5–26.9) 93 (72) 24.3 (16.2–32.3)
\37 55 (43) 24.3 (12.2–36.4) 0.01 47 (85) 0.004 Sens 50% Spec 78% 37.1 (10.6–63.6) 0.30
C37 74 (57) 13.1 (11.9–14.4) 46 (62) PPV 85% NPV 38% 31.0 (24.4–37.6)
\61
a 78 (60) 21.2 (11.9–30.6) 0.001 67 (86) \0.001 Sens 72% Spec 69% 36 (20.2–51.8) 0.38
C61
a 51 (40) 12.7 (10.8–14.6) 26 (51) PPV 86% NPV 49% 28.3 (13.1–43.5)
\200 106 (82) 26.4 (20.2–32.6) \0.001 84 (79) \0.001 Sens 90% Spec 39% 36.0 (24.0–48.0) 0.21
C200 23 (18) 10.4 (8.5–12.3) 9 (39) PPV 79% NPV 61% 28.3 (8.1–48.6)
\1,000 122 (95) 15.2 (12.3–18.2) \0.001 93 (76) \0.001 Sens 100% Spec 19% 34.0 (26.9–41.0) NA
C1,000 7 (5) 9.1 (0.8–17.4) 0 (0) PPV 76% NPV 100% NA
Sens sensitivity, Spec speciﬁcity, PPV positive predictive value, NPV negative predictive value, NA not applicable
a Optimal pretreatment CA 19-9 cutoff determined by receiver-operating characteristics (ROC) analysis
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FIG. 3 Restaging serum CA 19-9 levels of patients stratiﬁed by
resection and recurrence status at last follow-up. No patient with a
restaging CA 19-9 C1,000 U/ml underwent resection. Y-axis scale is
Log10. Horizontal line represents 37 U/ml
CA 19-9 in Neoadjuvant Chemoradiation 1799afﬁrm that both the restaging CA 19-9 level and the change
in CA 19-9 over the course of neoadjuvant therapy are
clinically relevant prognostic markers; in general, low re-
staging values are better than high values, and a decline in
CA 19-9 following induction therapy is more favorable
than a rise. However, four important caveats must be noted
with regard to these observations. First, the PPV of the
restaging CA 19-9 (86%) and the change in CA 19-9 (77%)
for completing all therapy including PD were similar to
that of the standard restaging evaluation (radiography and
physical examination) alone (86%). Second, restaging CA
19-9 and its change from the pretreatment level were both
associated with low NPV for competing PD; therefore,
neither test effectively excluded radiographically occult
metastatic disease at time of restaging. Third, although the
number of patients analyzed was relatively small, the
median survival of patients who underwent PD in the set-
ting of restaging CA 19-9 higher than all cutoff values, or
with stable or increased restaging CA 19-9, was similar to
the median survival of patients who underwent PD in
whom CA 19-9 levels were below each cutoff value or fell.
Finally, we were unable to demonstrate any correlation
between change in CA 19-9 level and response to treatment
as assessed histopathologically.
This study has two potential limitations. The ﬁrst is our
inability to differentiate between patients with low but
detectable level of CA 19-9 and patients with Lewis
a-b-
blood type who do not secrete CA 19-9.
22 The extent to
which our results have been inﬂuenced by this is difﬁcult to
determine as few studies have examined the prognosis of
Lewis antigen-negative patients. Available data suggest
that Lewis
a-b- patients have a prognosis similar to, but
perhaps even more favorable than, patients with CA 19-9
levels that are detectable but within the normal range or
slightly elevated.
11,31 Future trials are necessary to clearly
deﬁne the cancer biology of this group of patients.
A second potential limitation of this study is the
exclusion of signiﬁcant numbers of patients from analysis
due to elevation in serum bilirubin. This is particularly true
in the pretreatment setting: 67 of 174 patients with an
available pretreatment CA 19-9 level were excluded from
analysis due to concomitant obstructive jaundice. Hyper-
bilirubinemia, however, can confound measurements of
CA 19-9 levels and can introduce signiﬁcant error into
analyses in which CA 19-9 levels associated with both
normal and elevated bilirubin levels are considered.
7,21
Indeed, as we have argued, this represents a major limita-
tion of other studies.
10,15 Importantly, we found that the
demographics, clinical factors, and outcomes of patients
with and without an evaluable CA 19-9 at each time point
were comparable, suggesting that the exclusion criteria
used in this study actually strengthen our conclusions (as
opposed to weaken them).
In summary, based upon these data, we offer the fol-
lowing conclusions with regard to use of CA 19-9 in the
evaluation of patients with resectable PC treated with
neoadjuvant therapy. Serum CA 19-9 levels within the
normal range at diagnosis will most often remain normal
after induction therapy, and patients with a normal pre-
treatment CA 19-9 level can be expected to have favorable
prognosis compared with those with an elevated level.
Nonetheless, the presence of an elevated pretreatment
serum CA 19-9 level may not preclude completion of all
therapy to include PD. Similarly, both a low restaging CA
19-9 level and a decline over the course of induction
therapy are associated with undergoing successful PD;
however, a persistently elevated CA 19-9 level at restaging
does not reliably signify disease progression and may not
preclude successful PD. Based upon these ﬁndings, we
recommend that therapeutic decision-making with regard
to use of neoadjuvant therapy and PD for patients with
potentially resectable PC remain largely based on expert
clinical assessment and high-quality radiographic staging.
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